Neumora Therapeutics GAAP EPS of -$0.18 beats by $0.02
- Neumora Therapeutics press release (NMRA): Q3 GAAP EPS of -$0.18 beats by $0.02.
- As of September 30, 2026, Neumora had cash and cash equivalents of $85.7 million.
- Financial Guidance: Neumora is not providing updated financial runway guidance. As disclosed in our Quarterly
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.